Antipsychotic drugs :: pharmacology, side effects and abuse prevention /
Gespeichert in:
| Weitere Verfasser: | , , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
New York :
Nova Biomedical,
[2013]
|
| Schriftenreihe: | Psychiatry- theory, applications, and treatments series.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Beschreibung: | "Nova Biomedical" |
| Beschreibung: | 1 online resource. |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9781622574599 1622574591 |
Internformat
MARC
| LEADER | 00000cam a2200000 i 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn834604356 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 120614s2013 nyua ob 001 0 eng | ||
| 010 | |a 2019720654 | ||
| 040 | |a DLC |b eng |e rda |c DLC |d N$T |d UKMGB |d OCLCF |d D6H |d AGLDB |d Z5A |d VTS |d AU@ |d STF |d K6U |d YDXCP |d OCLCO |d OCLCQ |d OCLCO | ||
| 016 | 7 | |a 016156575 |2 Uk | |
| 020 | |a 9781622574599 |q ebook | ||
| 020 | |a 1622574591 | ||
| 020 | |z 9781621000716 |q (hbk.) | ||
| 020 | |z 1621000710 |q (hbk.) | ||
| 035 | |a (OCoLC)834604356 | ||
| 050 | 0 | 0 | |a RM333.5 |
| 060 | 4 | |a QV 77.9 | |
| 072 | 7 | |a MED |x 093000 |2 bisacsh | |
| 072 | 7 | |a MED |x 105020 |2 bisacsh | |
| 082 | 7 | |a 615.7/882 |2 23 | |
| 049 | |a MAIN | ||
| 245 | 0 | 0 | |a Antipsychotic drugs : |b pharmacology, side effects and abuse prevention / |c Thomas L. Schwartz, James Megna and Michael E. Topel, editors. |
| 264 | 1 | |a New York : |b Nova Biomedical, |c [2013] | |
| 300 | |a 1 online resource. | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 490 | 1 | |a Psychiatry- theory, applications, and treatments | |
| 500 | |a "Nova Biomedical" | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | |a Description based on print version record. | ||
| 505 | 0 | |a ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; Library of Congress Cataloging-in-Publication Data; Contents; Acknowledgment; Part I: History; Chapter 1: Antipsychotics: Where Have We Been? Where Are We Now?Where Are We Going?; Where Have We Been?; Where Are We Now; Where Are We Going; References; Chapter 2: Second Generation Antipsychotic Medications in the Treatment of Affective Disorders; Abstract; Introduction; Treatment-Resistant Depression; Fundamentals; Augmentation and Combination. | |
| 505 | 8 | |a Documentation during the Managementof Combination Strategies; Atypical Antipsychotic Medications As Augmentation; Amisulpiride; Aripiprazole; Asenapine; Clozapine; Olanzapine; Quetiapine; Risperidone; Sulpiride; Ziprazidone; Conclusion; Appendix 1. Second Generation Antipsychotics; Appendix 2. Acute Mania; Appendix 3. Bipolar Depression; Appendix 4. SGAs in MDD; References; Chapter 3: Antipsychotic Drugs and Children: The Good, the Bad, and What to Do About It; Abstract; Introduction; The Good; The Bad; What to Do About It; Conclusion; References. | |
| 505 | 8 | |a Part II: Pharmocokinetics / Pharmacodynamics / ApplicationsChapter 4: Pharmacokinetic Properties of Second Generation Antipsychotics; Abstract; Introduction; Aripiprazole; Olanzapine; Loperidone; Asenapine; Paliperidone; Risperidone; Lurasidone; Ziprasidone; Quetiapine; Conclusion; References; Chapter 5: Translating Basic Science into Clinical Practice While Dosing the Second Generation Antipsychotics; Abstract; Introduction; Second Generation Antipsychotic Dosing; Specific Dosing Strategies; Common Features; Risperidone; Paliperidone; Olanzapine; Quetiapine; Ziprasidone; Aripiprazole. | |
| 505 | 8 | |a AsenapineIloperidone; Cariprazine; Brexpipirazole; Summary; Conflict of Interest; Acknowledgments; References; Chapter 6: Depot Antipsychotics; Abstract; Introduction; History of Depot Antipsychotics; Advantages of Depot Antipsychotics; First-Generation Depot Antipsychotics; Fluphenazine Decanoate and Enanthate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Haloperidol Decanoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Second-Generation Depot Antipsychotics; Risperidone Long Acting Injection. | |
| 505 | 8 | |a Formulation and PharmacokineticsDosing and Administration; Efficacy; Safety; Paliperidone Palmitate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Olanzapine Pamoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Conclusions; Disadvantages of Depot Antipsychotic Medication; Why use Depot Antipsychotics?; References; Part III: Atypical Antipsycholtic Use Adverse Effects; Chapter 7: Attitudes toward Psychiatric Drug Treatment in Schizophrenia: Socio Demographic and Illness-Related Factors; Abstract; Introduction; Method. | |
| 650 | 0 | |a Antipsychotic drugs. |0 http://id.loc.gov/authorities/subjects/sh89002390 | |
| 650 | 0 | |a Antipsychotic drugs |x Side effects. |0 http://id.loc.gov/authorities/subjects/sh89002395 | |
| 650 | 0 | |a Medication abuse |x Prevention. | |
| 650 | 1 | 2 | |a Antipsychotic Agents |
| 650 | 6 | |a Neuroleptiques. | |
| 650 | 6 | |a Neuroleptiques |x Effets secondaires. | |
| 650 | 7 | |a MEDICAL |x Pain Medicine. |2 bisacsh | |
| 650 | 7 | |a MEDICAL |x Psychiatry |x Psychopharmacology. |2 bisacsh | |
| 650 | 7 | |a Antipsychotic drugs |2 fast | |
| 650 | 7 | |a Antipsychotic drugs |x Side effects |2 fast | |
| 650 | 7 | |a Medication abuse |x Prevention |2 fast | |
| 700 | 1 | |a Schwartz, Thomas L., |e editor. | |
| 700 | 1 | |a Megna, James, |e editor. | |
| 700 | 1 | |a Topel, Michael E., |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Antipsychotic drugs |z 9781621000716 |w (DLC) 2012941953 |
| 830 | 0 | |a Psychiatry- theory, applications, and treatments series. |0 http://id.loc.gov/authorities/names/n2009185501 | |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=548903 |3 Volltext |
| 938 | |a YBP Library Services |b YANK |n 10394893 | ||
| 938 | |a EBSCOhost |b EBSC |n 548903 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn834604356 |
|---|---|
| _version_ | 1816882227526500352 |
| adam_text | |
| any_adam_object | |
| author2 | Schwartz, Thomas L. Megna, James Topel, Michael E. |
| author2_role | edt edt edt |
| author2_variant | t l s tl tls j m jm m e t me met |
| author_facet | Schwartz, Thomas L. Megna, James Topel, Michael E. |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | R - Medicine |
| callnumber-label | RM333 |
| callnumber-raw | RM333.5 |
| callnumber-search | RM333.5 |
| callnumber-sort | RM 3333.5 |
| callnumber-subject | RM - Therapeutics and Pharmacology |
| collection | ZDB-4-EBA |
| contents | ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; Library of Congress Cataloging-in-Publication Data; Contents; Acknowledgment; Part I: History; Chapter 1: Antipsychotics: Where Have We Been? Where Are We Now?Where Are We Going?; Where Have We Been?; Where Are We Now; Where Are We Going; References; Chapter 2: Second Generation Antipsychotic Medications in the Treatment of Affective Disorders; Abstract; Introduction; Treatment-Resistant Depression; Fundamentals; Augmentation and Combination. Documentation during the Managementof Combination Strategies; Atypical Antipsychotic Medications As Augmentation; Amisulpiride; Aripiprazole; Asenapine; Clozapine; Olanzapine; Quetiapine; Risperidone; Sulpiride; Ziprazidone; Conclusion; Appendix 1. Second Generation Antipsychotics; Appendix 2. Acute Mania; Appendix 3. Bipolar Depression; Appendix 4. SGAs in MDD; References; Chapter 3: Antipsychotic Drugs and Children: The Good, the Bad, and What to Do About It; Abstract; Introduction; The Good; The Bad; What to Do About It; Conclusion; References. Part II: Pharmocokinetics / Pharmacodynamics / ApplicationsChapter 4: Pharmacokinetic Properties of Second Generation Antipsychotics; Abstract; Introduction; Aripiprazole; Olanzapine; Loperidone; Asenapine; Paliperidone; Risperidone; Lurasidone; Ziprasidone; Quetiapine; Conclusion; References; Chapter 5: Translating Basic Science into Clinical Practice While Dosing the Second Generation Antipsychotics; Abstract; Introduction; Second Generation Antipsychotic Dosing; Specific Dosing Strategies; Common Features; Risperidone; Paliperidone; Olanzapine; Quetiapine; Ziprasidone; Aripiprazole. AsenapineIloperidone; Cariprazine; Brexpipirazole; Summary; Conflict of Interest; Acknowledgments; References; Chapter 6: Depot Antipsychotics; Abstract; Introduction; History of Depot Antipsychotics; Advantages of Depot Antipsychotics; First-Generation Depot Antipsychotics; Fluphenazine Decanoate and Enanthate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Haloperidol Decanoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Second-Generation Depot Antipsychotics; Risperidone Long Acting Injection. Formulation and PharmacokineticsDosing and Administration; Efficacy; Safety; Paliperidone Palmitate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Olanzapine Pamoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Conclusions; Disadvantages of Depot Antipsychotic Medication; Why use Depot Antipsychotics?; References; Part III: Atypical Antipsycholtic Use Adverse Effects; Chapter 7: Attitudes toward Psychiatric Drug Treatment in Schizophrenia: Socio Demographic and Illness-Related Factors; Abstract; Introduction; Method. |
| ctrlnum | (OCoLC)834604356 |
| dewey-full | 615.7/882 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7/882 |
| dewey-search | 615.7/882 |
| dewey-sort | 3615.7 3882 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>05466cam a2200685 i 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn834604356</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">120614s2013 nyua ob 001 0 eng </controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="a"> 2019720654</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DLC</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">DLC</subfield><subfield code="d">N$T</subfield><subfield code="d">UKMGB</subfield><subfield code="d">OCLCF</subfield><subfield code="d">D6H</subfield><subfield code="d">AGLDB</subfield><subfield code="d">Z5A</subfield><subfield code="d">VTS</subfield><subfield code="d">AU@</subfield><subfield code="d">STF</subfield><subfield code="d">K6U</subfield><subfield code="d">YDXCP</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">016156575</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781622574599</subfield><subfield code="q">ebook</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1622574591</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9781621000716</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">1621000710</subfield><subfield code="q">(hbk.)</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)834604356</subfield></datafield><datafield tag="050" ind1="0" ind2="0"><subfield code="a">RM333.5</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QV 77.9</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">093000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">105020</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.7/882</subfield><subfield code="2">23</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Antipsychotic drugs :</subfield><subfield code="b">pharmacology, side effects and abuse prevention /</subfield><subfield code="c">Thomas L. Schwartz, James Megna and Michael E. Topel, editors.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York :</subfield><subfield code="b">Nova Biomedical,</subfield><subfield code="c">[2013]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Psychiatry- theory, applications, and treatments</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"Nova Biomedical"</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on print version record.</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; Library of Congress Cataloging-in-Publication Data; Contents; Acknowledgment; Part I: History; Chapter 1: Antipsychotics: Where Have We Been? Where Are We Now?Where Are We Going?; Where Have We Been?; Where Are We Now; Where Are We Going; References; Chapter 2: Second Generation Antipsychotic Medications in the Treatment of Affective Disorders; Abstract; Introduction; Treatment-Resistant Depression; Fundamentals; Augmentation and Combination.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Documentation during the Managementof Combination Strategies; Atypical Antipsychotic Medications As Augmentation; Amisulpiride; Aripiprazole; Asenapine; Clozapine; Olanzapine; Quetiapine; Risperidone; Sulpiride; Ziprazidone; Conclusion; Appendix 1. Second Generation Antipsychotics; Appendix 2. Acute Mania; Appendix 3. Bipolar Depression; Appendix 4. SGAs in MDD; References; Chapter 3: Antipsychotic Drugs and Children: The Good, the Bad, and What to Do About It; Abstract; Introduction; The Good; The Bad; What to Do About It; Conclusion; References.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Part II: Pharmocokinetics / Pharmacodynamics / ApplicationsChapter 4: Pharmacokinetic Properties of Second Generation Antipsychotics; Abstract; Introduction; Aripiprazole; Olanzapine; Loperidone; Asenapine; Paliperidone; Risperidone; Lurasidone; Ziprasidone; Quetiapine; Conclusion; References; Chapter 5: Translating Basic Science into Clinical Practice While Dosing the Second Generation Antipsychotics; Abstract; Introduction; Second Generation Antipsychotic Dosing; Specific Dosing Strategies; Common Features; Risperidone; Paliperidone; Olanzapine; Quetiapine; Ziprasidone; Aripiprazole.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">AsenapineIloperidone; Cariprazine; Brexpipirazole; Summary; Conflict of Interest; Acknowledgments; References; Chapter 6: Depot Antipsychotics; Abstract; Introduction; History of Depot Antipsychotics; Advantages of Depot Antipsychotics; First-Generation Depot Antipsychotics; Fluphenazine Decanoate and Enanthate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Haloperidol Decanoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Second-Generation Depot Antipsychotics; Risperidone Long Acting Injection.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Formulation and PharmacokineticsDosing and Administration; Efficacy; Safety; Paliperidone Palmitate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Olanzapine Pamoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Conclusions; Disadvantages of Depot Antipsychotic Medication; Why use Depot Antipsychotics?; References; Part III: Atypical Antipsycholtic Use Adverse Effects; Chapter 7: Attitudes toward Psychiatric Drug Treatment in Schizophrenia: Socio Demographic and Illness-Related Factors; Abstract; Introduction; Method.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antipsychotic drugs.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh89002390</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Antipsychotic drugs</subfield><subfield code="x">Side effects.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh89002395</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Medication abuse</subfield><subfield code="x">Prevention.</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Antipsychotic Agents</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Neuroleptiques.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Neuroleptiques</subfield><subfield code="x">Effets secondaires.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pain Medicine.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Psychiatry</subfield><subfield code="x">Psychopharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antipsychotic drugs</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antipsychotic drugs</subfield><subfield code="x">Side effects</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medication abuse</subfield><subfield code="x">Prevention</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schwartz, Thomas L.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Megna, James,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Topel, Michael E.,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Antipsychotic drugs</subfield><subfield code="z">9781621000716</subfield><subfield code="w">(DLC) 2012941953</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Psychiatry- theory, applications, and treatments series.</subfield><subfield code="0">http://id.loc.gov/authorities/names/n2009185501</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=548903</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">10394893</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">548903</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn834604356 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:25:16Z |
| institution | BVB |
| isbn | 9781622574599 1622574591 |
| language | English |
| lccn | 2019720654 |
| oclc_num | 834604356 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource. |
| psigel | ZDB-4-EBA |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | Nova Biomedical, |
| record_format | marc |
| series | Psychiatry- theory, applications, and treatments series. |
| series2 | Psychiatry- theory, applications, and treatments |
| spelling | Antipsychotic drugs : pharmacology, side effects and abuse prevention / Thomas L. Schwartz, James Megna and Michael E. Topel, editors. New York : Nova Biomedical, [2013] 1 online resource. text txt rdacontent computer c rdamedia online resource cr rdacarrier Psychiatry- theory, applications, and treatments "Nova Biomedical" Includes bibliographical references and index. Description based on print version record. ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; Library of Congress Cataloging-in-Publication Data; Contents; Acknowledgment; Part I: History; Chapter 1: Antipsychotics: Where Have We Been? Where Are We Now?Where Are We Going?; Where Have We Been?; Where Are We Now; Where Are We Going; References; Chapter 2: Second Generation Antipsychotic Medications in the Treatment of Affective Disorders; Abstract; Introduction; Treatment-Resistant Depression; Fundamentals; Augmentation and Combination. Documentation during the Managementof Combination Strategies; Atypical Antipsychotic Medications As Augmentation; Amisulpiride; Aripiprazole; Asenapine; Clozapine; Olanzapine; Quetiapine; Risperidone; Sulpiride; Ziprazidone; Conclusion; Appendix 1. Second Generation Antipsychotics; Appendix 2. Acute Mania; Appendix 3. Bipolar Depression; Appendix 4. SGAs in MDD; References; Chapter 3: Antipsychotic Drugs and Children: The Good, the Bad, and What to Do About It; Abstract; Introduction; The Good; The Bad; What to Do About It; Conclusion; References. Part II: Pharmocokinetics / Pharmacodynamics / ApplicationsChapter 4: Pharmacokinetic Properties of Second Generation Antipsychotics; Abstract; Introduction; Aripiprazole; Olanzapine; Loperidone; Asenapine; Paliperidone; Risperidone; Lurasidone; Ziprasidone; Quetiapine; Conclusion; References; Chapter 5: Translating Basic Science into Clinical Practice While Dosing the Second Generation Antipsychotics; Abstract; Introduction; Second Generation Antipsychotic Dosing; Specific Dosing Strategies; Common Features; Risperidone; Paliperidone; Olanzapine; Quetiapine; Ziprasidone; Aripiprazole. AsenapineIloperidone; Cariprazine; Brexpipirazole; Summary; Conflict of Interest; Acknowledgments; References; Chapter 6: Depot Antipsychotics; Abstract; Introduction; History of Depot Antipsychotics; Advantages of Depot Antipsychotics; First-Generation Depot Antipsychotics; Fluphenazine Decanoate and Enanthate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Haloperidol Decanoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Second-Generation Depot Antipsychotics; Risperidone Long Acting Injection. Formulation and PharmacokineticsDosing and Administration; Efficacy; Safety; Paliperidone Palmitate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Olanzapine Pamoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Conclusions; Disadvantages of Depot Antipsychotic Medication; Why use Depot Antipsychotics?; References; Part III: Atypical Antipsycholtic Use Adverse Effects; Chapter 7: Attitudes toward Psychiatric Drug Treatment in Schizophrenia: Socio Demographic and Illness-Related Factors; Abstract; Introduction; Method. Antipsychotic drugs. http://id.loc.gov/authorities/subjects/sh89002390 Antipsychotic drugs Side effects. http://id.loc.gov/authorities/subjects/sh89002395 Medication abuse Prevention. Antipsychotic Agents Neuroleptiques. Neuroleptiques Effets secondaires. MEDICAL Pain Medicine. bisacsh MEDICAL Psychiatry Psychopharmacology. bisacsh Antipsychotic drugs fast Antipsychotic drugs Side effects fast Medication abuse Prevention fast Schwartz, Thomas L., editor. Megna, James, editor. Topel, Michael E., editor. Print version: Antipsychotic drugs 9781621000716 (DLC) 2012941953 Psychiatry- theory, applications, and treatments series. http://id.loc.gov/authorities/names/n2009185501 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=548903 Volltext |
| spellingShingle | Antipsychotic drugs : pharmacology, side effects and abuse prevention / Psychiatry- theory, applications, and treatments series. ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; ANTIPSYCHOTIC DRUGS: PHARMACOLOGY, SIDE EFFECTS AND ABUSE PREVENTION; Library of Congress Cataloging-in-Publication Data; Contents; Acknowledgment; Part I: History; Chapter 1: Antipsychotics: Where Have We Been? Where Are We Now?Where Are We Going?; Where Have We Been?; Where Are We Now; Where Are We Going; References; Chapter 2: Second Generation Antipsychotic Medications in the Treatment of Affective Disorders; Abstract; Introduction; Treatment-Resistant Depression; Fundamentals; Augmentation and Combination. Documentation during the Managementof Combination Strategies; Atypical Antipsychotic Medications As Augmentation; Amisulpiride; Aripiprazole; Asenapine; Clozapine; Olanzapine; Quetiapine; Risperidone; Sulpiride; Ziprazidone; Conclusion; Appendix 1. Second Generation Antipsychotics; Appendix 2. Acute Mania; Appendix 3. Bipolar Depression; Appendix 4. SGAs in MDD; References; Chapter 3: Antipsychotic Drugs and Children: The Good, the Bad, and What to Do About It; Abstract; Introduction; The Good; The Bad; What to Do About It; Conclusion; References. Part II: Pharmocokinetics / Pharmacodynamics / ApplicationsChapter 4: Pharmacokinetic Properties of Second Generation Antipsychotics; Abstract; Introduction; Aripiprazole; Olanzapine; Loperidone; Asenapine; Paliperidone; Risperidone; Lurasidone; Ziprasidone; Quetiapine; Conclusion; References; Chapter 5: Translating Basic Science into Clinical Practice While Dosing the Second Generation Antipsychotics; Abstract; Introduction; Second Generation Antipsychotic Dosing; Specific Dosing Strategies; Common Features; Risperidone; Paliperidone; Olanzapine; Quetiapine; Ziprasidone; Aripiprazole. AsenapineIloperidone; Cariprazine; Brexpipirazole; Summary; Conflict of Interest; Acknowledgments; References; Chapter 6: Depot Antipsychotics; Abstract; Introduction; History of Depot Antipsychotics; Advantages of Depot Antipsychotics; First-Generation Depot Antipsychotics; Fluphenazine Decanoate and Enanthate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Haloperidol Decanoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Second-Generation Depot Antipsychotics; Risperidone Long Acting Injection. Formulation and PharmacokineticsDosing and Administration; Efficacy; Safety; Paliperidone Palmitate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Olanzapine Pamoate; Formulation and Pharmacokinetics; Dosing and Administration; Efficacy; Safety; Conclusions; Disadvantages of Depot Antipsychotic Medication; Why use Depot Antipsychotics?; References; Part III: Atypical Antipsycholtic Use Adverse Effects; Chapter 7: Attitudes toward Psychiatric Drug Treatment in Schizophrenia: Socio Demographic and Illness-Related Factors; Abstract; Introduction; Method. Antipsychotic drugs. http://id.loc.gov/authorities/subjects/sh89002390 Antipsychotic drugs Side effects. http://id.loc.gov/authorities/subjects/sh89002395 Medication abuse Prevention. Antipsychotic Agents Neuroleptiques. Neuroleptiques Effets secondaires. MEDICAL Pain Medicine. bisacsh MEDICAL Psychiatry Psychopharmacology. bisacsh Antipsychotic drugs fast Antipsychotic drugs Side effects fast Medication abuse Prevention fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh89002390 http://id.loc.gov/authorities/subjects/sh89002395 |
| title | Antipsychotic drugs : pharmacology, side effects and abuse prevention / |
| title_auth | Antipsychotic drugs : pharmacology, side effects and abuse prevention / |
| title_exact_search | Antipsychotic drugs : pharmacology, side effects and abuse prevention / |
| title_full | Antipsychotic drugs : pharmacology, side effects and abuse prevention / Thomas L. Schwartz, James Megna and Michael E. Topel, editors. |
| title_fullStr | Antipsychotic drugs : pharmacology, side effects and abuse prevention / Thomas L. Schwartz, James Megna and Michael E. Topel, editors. |
| title_full_unstemmed | Antipsychotic drugs : pharmacology, side effects and abuse prevention / Thomas L. Schwartz, James Megna and Michael E. Topel, editors. |
| title_short | Antipsychotic drugs : |
| title_sort | antipsychotic drugs pharmacology side effects and abuse prevention |
| title_sub | pharmacology, side effects and abuse prevention / |
| topic | Antipsychotic drugs. http://id.loc.gov/authorities/subjects/sh89002390 Antipsychotic drugs Side effects. http://id.loc.gov/authorities/subjects/sh89002395 Medication abuse Prevention. Antipsychotic Agents Neuroleptiques. Neuroleptiques Effets secondaires. MEDICAL Pain Medicine. bisacsh MEDICAL Psychiatry Psychopharmacology. bisacsh Antipsychotic drugs fast Antipsychotic drugs Side effects fast Medication abuse Prevention fast |
| topic_facet | Antipsychotic drugs. Antipsychotic drugs Side effects. Medication abuse Prevention. Antipsychotic Agents Neuroleptiques. Neuroleptiques Effets secondaires. MEDICAL Pain Medicine. MEDICAL Psychiatry Psychopharmacology. Antipsychotic drugs Antipsychotic drugs Side effects Medication abuse Prevention |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=548903 |
| work_keys_str_mv | AT schwartzthomasl antipsychoticdrugspharmacologysideeffectsandabuseprevention AT megnajames antipsychoticdrugspharmacologysideeffectsandabuseprevention AT topelmichaele antipsychoticdrugspharmacologysideeffectsandabuseprevention |